[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"central-nervous-system-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:central-nervous-system-infections":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,74,99,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100548211","infectious-disease-registry-biobank-100548211",false,"NCT06418048","INfectious DIsease REgistry BIObank","Prospective Registry and Biobank of Patients With Infectious Diseases","INDI-REBIO","Inclusion Criteria:\n\n* Patients with clinically suspected or microbiologically documented infectious diseases (bacterial, viral, fungal or parasitic);\n* At least 18 years of age or older;\n* Able to provide informed consent;\n* Participants who are unable to understand the study protocol or are unable to give informed consent, but have a legal representative\n\nExclusion Criteria:\n\n\\- Participants who are unable to understand the study protocol or are unable to give informed consent, and have no legal representative.","ALL","18 Years",{"count":20,"type":21},10000,"ESTIMATED","20 Years","OBSERVATIONAL","Prospective observational study designed to describe the clinical, laboratory, imaging, microbiological characteristics and treatment of specific infectious diseases, with the addition of a dedicated biobank.",[26,27,28,29,30,31,32],"Bloodstream Infections","Central Nervous System Infections","Bone and Joint Infections","Endovascular Infections","Infective Endocarditis","CIED-related Infections","Vertebral Osteomyelitis","RECRUITING","2026-04-15",{"date":36,"type":37},"2026-04-20","ACTUAL",{"date":39,"type":37},"2024-02-01",{"date":41,"type":21},"2044-07-31",{"name":43,"class":44},"IRCCS San Raffaele","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100543618","safety-and-efficacy-of-ventricular-irrigation-for-ventriculitis-100543618","NCT06358209","Safety and Efficacy of Ventricular Irrigation for Ventriculitis","Safety and Efficacy of Ventricular Irrigation for Ventriculitis: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18-65 years old;\n* CSF is purulent (it appears cloudy or yellow) and white blood cell count over 1000×10\\^6\u002FL.\n* Fever (\\>38.0°C)\n* Meet at least one of the following: 1. Patient has organism(s) identified from CSF by a culture or non-culture based microbiologic testing method; 2. Cranial CT or MRI indicating intraventricular floccule or pus.\n* With consent form\n\nExclusion Criteria:\n\n* With GCS score of 3\n* With unstable vital signs such as no spontaneous breathing and blood pressure maintenance drugs\n* With severe propensity for bleeding (Such as coagulation dysfunction, active bleeding, etc.), and unable to tolerate the surgical procedures or operations related to ventricular irrigation treatment.\n* Pregnant or lactating women","65 Years",{"count":55,"type":21},310,"INTERVENTIONAL",[58],"NA","Ventriculitis is a severe infectious disease of the central nervous system with diverse etiologies. Currently, the treatment for ventriculitis is challenging, with poor prognosis. The mortality rate of ventriculitis is generally reported to be higher than 30%, with the highest reaching over 75%. Even among survivors, over 60% suffer from a variety of neurological sequelae, including cognitive impairment, gait disturbances, paralysis, behavioral disorders, and epilepsy.\n\nCurrently, treatments for ventriculitis recommended by guidelines primarily focus on the selection and administration of antibiotics, while the effects of surgical interventions have not been fully elucidated. In recent years, several studies have explored the use of ventricular irrigation in ventriculitis, indicating that ventricular irrigation techniques may accelerate the control of ventricular infection, mitigate damage to the central nervous system caused by infections, improve the prognosis of ventriculitis, and reduce complications such as hydrocephalus. However, current studies are still relatively scarce, and mostly case reports and retrospective studies. High-quality evidence is still lacking for the application of ventricular irrigation in ventriculitis.\n\nThis multicenter randomized controlled trial aims to explore the safety and effectiveness of ventricular irrigation compared to conventional treatment for ventriculitis, analyze the effectiveness of ventricular irrigation across different pathogen subgroups, and investigate independent risk factors for different prognostic states in patients with ventriculitis.",[27],[62,63],"Ventriculitis","Ventricular irrigation","2026-02-23",{"date":66,"type":37},"2026-02-25",{"date":68,"type":37},"2025-07-01",{"date":70,"type":21},"2028-12-31",{"name":72,"class":44},"RenJi Hospital",35,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":18,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100570107","comparing-tigecycline-vs-colistimethate-in-cns-infections-100570107","NCT06702943","Comparing Tigecycline Vs. Colistimethate in CNS Infections","Comparative Study of the Efficacy and Safety of Tigecycline Based Regimen Versus Colistimethate Sodium-based Regimen in Patients with Central Nervous System Bacterial Infections","Inclusion Criteria:\n\n* Pediatric patients aged 1 month to 18 years.\n* Presence of CNS infection symptoms such as fever, altered mental status, and positive cerebrospinal fluid (CSF) findings.\n* EVD placement for managing CNS infections.\n\nExclusion Criteria:\n\n* Known allergy to tigecycline or colistimethate sodium. Patients with concurrent severe comorbid conditions that may confound study results.\n\nNeonates (less than 1 month old).","28 Days",{"count":83,"type":21},70,"This observational study compares the efficacy and safety of tigecycline, an alternative antibiotic with broad-spectrum activity, versus the standard colistimethate sodium-based regimen in managing these infections in pediatric patients.\n\nInclusion Criteria:\n\nPediatric patients aged 1 month to 18 years. Presence of CNS infection symptoms such as fever, altered mental status, and positive cerebrospinal fluid (CSF) findings.\n\nEVD placement for managing CNS infections.\n\nExclusion Criteria:\n\nKnown allergy to tigecycline or colistimethate sodium. Patients with concurrent severe comorbid conditions that may confound study results.\n\nNeonates (less than 1 month old), pregnant, or breastfeeding patients.\n\nOutcome Measures:\n\nPrimary Outcomes: Clinical cure (resolution of infection symptoms) and microbiological cure (sterilization of CSF cultures).\n\nSecondary Outcomes: Mortality rates and adverse drug events, such as nephrotoxicity, hepatotoxicity, chemical meningitis, or seizures.",[27],[87,88],"Central nervous system infections","MDR bacteria","NOT_YET_RECRUITING","2024-11-22",{"date":92,"type":37},"2024-11-25",{"date":94,"type":21},"2024-12-01",{"date":96,"type":21},"2027-06",{"name":98,"class":44},"Ain Shams University",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":109,"conditions":110,"keywords":122,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100317883","central-nervous-system-infections-in-denmark-100317883","NCT03418441","Central Nervous System Infections in Denmark","Danish Study Group of Infections of the Brain: A Nationwide Prospective Observational Cohort Study of All Central Nervous System Infections in Adults at Departments of Infectious Diseases in Denmark","DASGIB","Definitions of central nervous system infections:\n\nFor all cases with unproven aetiologies no alternative diagnosis than CNS infection is thought more likely after completed multidisciplinary diagnostic work-up.\n\nViral meningitis inclusion criteria\n\n\\- All patients have to have a clinical presentation consistent with non-bacterial meningitis (e.g. headache, neck stiffness, photo- or phonophobia, fever)\n\nand\n\nCerebrospinal fluid leukocytes\\>10 cells\u002Fml\n\nPatients with viral meningitis with undetermined pathogen have to have:\n\n* CSF leukocytes\\> 10\u002FmL and no other more probable diagnosis assessed by the local investigator.\n\nIn case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.\n\nBacterial meningitis inclusion criteria - All patients have to have a clinical presentation consistent with bacterial meningitis (e.g. headache, neck stiffness, fever, altered mental status)\n\nand\n\nProven bacterial aetiology (CSF or blood culture\u002FDNA based technology or antigen tests)\n\nPatients with bacterial meningitis in whom the bacteria cannot not be cultured or identified by DNA-based technologies have to have:\n\n\\- CSF leukocytes\\> 10\u002FmL and no other more probable diagnosis assessed by the local investigator.\n\nIn case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.\n\nEncephalitis inclusion criteria - All patients have to have a clinical presentation consistent with encephalitis (e.g. headache, fever, focal neurological deficit, altered mental status \\>24 hours) as defined by the International Encephalitis Consortium (Venkatesan A et al., Clin Infect Dis 2013; doi:10.1093\u002Fcid\u002Fcit458.).\n\nEncephalitis exclusion criteria\n\n\\- We exclude cases of proven or suspected autoimmune encephalitis.\n\nPrimary brain abscess inclusion criteria\n\n\\- All patient have a clinical presentation consistent with brain abscess (e.g. headache, focal neurological deficit, mass lesion on cranial imaging)\n\nand\n\n\\- Proven microbiological aetiology by culture\u002FDNA-based technology from pus from brain abscess or blood or CSF\n\nor\n\n\\- Aspiration of pus from the brain abscess\n\nor\n\n\\- Response to antimicrobial treatment\n\nor\n\n\\- Tumour ruled out\n\nor\n\n\\- Tumour thought less probable than abscess on MRI using diffusion weighted imaging (DWI) and apparent diffusion coefficient (ADC) sequences.\n\nLyme neuroborreliosis inclusion criteria\n\n\\- A clinical presentation consistent with neuroborreliosis (e.g. radiculopathy)\n\nand\n\n\\- CSF pleocytosis\\>10 leukocytes\u002FmL\n\nand\n\n\\- Positive intrathecal B.burgdorferi antibody production index.\n\nNeurosyphilis inclusion criteria - A clinical presentation consistent with neurosyphilis (e.g. 'encephalitis-like symptoms', dementia, ocular or otogenic syphilis)\n\nand either\n\n\\- Positive syphilis serology in serum combined with CSF leukocytes\\>10\u002FmL\n\nor\n\n\\- CSF syphilis antibodies.",{"count":108,"type":21},1900,"The Danish Study Group of Infections of the Brain is a collaboration between all departments of infectious diseases in Denmark. The investigators aim to monitor epidemiological trends in central nervous system (CNS) infections by a prospective registration of clinical characteristics and outcome of all adult (\\>17 years of age) patients with community-acquired CNS infections diagnosed and\u002For treated at departments of infectious diseases in Denmark since 1st of January 2015.",[27,111,112,113,114,115,116,117,118,119,120,121],"Bacterial Meningitis","Viral Meningitis","Aseptic Meningitis","Encephalitis","Brain Abscess","Neuroborreliosis","Neurosyphilis","Lyme Disease","Tertiary Syphilis","Cerebral Abscess","Meningitis",[123,124,27,121,114,125,126,116,117,127],"Nationwide prospective observational cohort study","Epidemiology","Brain abscess","Lyme disease","Tertiary syphilis","2024-05-15",{"date":130,"type":37},"2024-05-16",{"date":132,"type":37},"2015-01-01",{"date":134,"type":21},"2030-01-01",{"name":136,"class":44},"Aalborg University Hospital",8,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":56,"phases":147,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100547790","effect-of-a-bundle-of-interventions-on-the-outcomes-of-patients-with-intracranial-devices-icp-monitor-e-evd-100547790","NCT06412549","Effect of a Bundle of Interventions on the Outcomes of Patients With Intracranial Devices (ICP Monitor e EVD)","IMPACTO MR: Effect of a Bundle of Interventions on Patients With Central Nervous System Devices - Project Platform Supporting the National Action Plan for Prevention and Control of Antimicrobial Resistance","Inclusion Criteria:\n\n* Adult patients with intracranial pressure monitoring catheters (intraventricular or intraparenchymal) and\u002For external ventricular drain.\n* The patient can be included from the moment the catheter is implanted, without there being a minimum time for inclusion.\n\nExclusion Criteria:\n\n* Suspected or confirmed brain death.",{"count":146,"type":21},1300,[58],"Non-randomized clinical trial conducted in the adult ICUs of Brazilian hospitals participating in the IMPACTO MR Platform, involving adult patients using an intracranial pressure monitoring catheter device or external ventricular drain.\n\nThe study will test the hypothesis that the intervention bundle, following ANVISA recommendations for care practices, will reduce the rates of central nervous system infections associated with ICP and EVD devices.\n\nThis reduction is expected to lead to more accurate diagnoses, decreased antibiotic usage, shortened ICU and hospital stays, and reduced hospital costs.",[27],[151,152,153,154],"Bacterial resistance","Health care","Central nervous systen infection","Multi-resistant microorganism","2024-05-08",{"date":157,"type":37},"2024-05-14",{"date":159,"type":21},"2024-06-01",{"date":161,"type":21},"2026-12-31",{"name":163,"class":44},"Beneficência Portuguesa de São Paulo"]